Five Below outlines $4.21B-$4.33B revenue guidance for FY2025 amid tariff impacts
Discover key takeaways from Five Below's Q4 2024 earnings call. Learn about growth strategies, tariff impacts, and operational excellence initiatives.
ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025
Discover scPharmaceuticals' Q4 2024 achievements, including FUROSCIX's CKD approval, Medicare redesign insights, and strategies for 2025 growth.
Analyst reboots Nike stock price target ahead of earnings
But the Nike veteran, who freely admits that he has "an irrational love for this company," was also honest about the state of ...